» Articles » PMID: 36291106

Chromosomal Heteromorphisms and Cancer Susceptibility Revisited

Overview
Journal Cells
Publisher MDPI
Date 2022 Oct 27
PMID 36291106
Authors
Affiliations
Soon will be listed here.
Abstract

Chromosomal heteromorphisms (CHs) are a part of genetic variation in man. The past literature largely posited whether CHs could be correlated with the development of malignancies. While this possibility seemed closed by end of the 1990s, recent data have raised the question again on the potential influences of repetitive DNA elements, the main components of CHs, in cancer susceptibility. Such new evidence for a potential role of CHs in cancer can be found in the following observations: (i) amplification and/or epigenetic alterations of CHs are routinely reported in tumors; (ii) the expression of CH-derived RNA in embryonal and other cells under stress, including cancer cells; (iii) the expression of parts of CH-DNA as long noncoding RNAs; plus (iv) theories that suggest a possible application of the "two-hit model" for euchromatic copy number variants (CNVs). Herein, these points are discussed in detail, which leads to the conclusion that CHs are by far not given sufficient consideration in routine cytogenetic analysis, e.g., leukemias and lymphomas, and need more attention in future research settings including solid tumors. This heightened focus may only be achieved by approaches other than standard sequencing or chromosomal microarrays, as these techniques are at a minimum impaired in their ability to detect, if not blind to, (highly) repetitive DNA sequences.

Citing Articles

Improving prenatal diagnosis with combined karyotyping, CNV-seq and QF-PCR: a comprehensive analysis of chromosomal abnormalities in high-risk pregnancies.

Liu J, Wang S, Luo L, Guo Y Front Genet. 2025; 15:1517270.

PMID: 39872004 PMC: 11770095. DOI: 10.3389/fgene.2024.1517270.


Challenges in classifying human chromosomal heteromorphisms using banding cytogenetics: From controversial guidelines to the need for a universal scoring system.

Pires S, Jorge P, Liehr T, Oliva-Teles N Hum Genome Var. 2024; 11(1):38.

PMID: 39443464 PMC: 11499882. DOI: 10.1038/s41439-024-00295-8.


A Paradoxical Role for Somatic Chromosomal Mosaicism and Chromosome Instability in Cancer: Theoretical and Technological Aspects.

Iourov I, Vorsanova S, Yurov Y Methods Mol Biol. 2024; 2825:67-78.

PMID: 38913303 DOI: 10.1007/978-1-0716-3946-7_3.


Overexpression of Pericentromeric HSAT2 DNA Increases Expression of EMT Markers in Human Epithelial Cancer Cell Lines.

Ponomartsev N, Zilov D, Gushcha E, Travina A, Sergeev A, Enukashvily N Int J Mol Sci. 2023; 24(8).

PMID: 37108080 PMC: 10138405. DOI: 10.3390/ijms24086918.


Challenges and Opportunities for Clinical Cytogenetics in the 21st Century.

Heng E, Thanedar S, Heng H Genes (Basel). 2023; 14(2).

PMID: 36833419 PMC: 9956237. DOI: 10.3390/genes14020493.

References
1.
Harel T, Lupski J . Genomic disorders 20 years on-mechanisms for clinical manifestations. Clin Genet. 2017; 93(3):439-449. DOI: 10.1111/cge.13146. View

2.
Neglia M, Bertoni L, Zoli W, Giulotto E . Amplification of the pericentromeric region of chromosome 1 in a newly established colon carcinoma cell line. Cancer Genet Cytogenet. 2003; 142(2):99-106. DOI: 10.1016/s0165-4608(02)00802-6. View

3.
Huffman J, Butler-Laporte G, Khan A, Pairo-Castineira E, Drivas T, Peloso G . Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19. Nat Genet. 2022; 54(2):125-127. PMC: 8837537. DOI: 10.1038/s41588-021-00996-8. View

4.
Albers C, Paul D, Schulze H, Freson K, Stephens J, Smethurst P . Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndrome. Nat Genet. 2012; 44(4):435-9, S1-2. PMC: 3428915. DOI: 10.1038/ng.1083. View

5.
. Mapping the human genetic architecture of COVID-19. Nature. 2021; 600(7889):472-477. PMC: 8674144. DOI: 10.1038/s41586-021-03767-x. View